<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "http://dtd.nlm.nih.gov/publishing/2.3/journalpublishing.dtd">
<article article-type="research-article">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher">aac</journal-id>
            <journal-title>Antimicrobial Agents and Chemotherapy</journal-title>
            <abbrev-journal-title>ANTIMICROB AGENTS CHEMOTHER</abbrev-journal-title>
            <issn>0066-4804</issn>
            <publisher>
                <publisher-name>American Society for Microbiology</publisher-name>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="publisher-id">56/9/4594</article-id>
            <article-id pub-id-type="publisher-id">AAC.00407-12</article-id>
            <article-id pub-id-type="doi">10.1128/AAC.00407-12</article-id>
            <article-categories>
                <subj-group>
                    <subject>Susceptibility</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Anti-<italic>Helicobacter pylori</italic> Potential of Artemisinin
                    and Its Derivatives</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Goswami</surname>
                        <given-names>Suchandra</given-names>
                    </name>
                    <xref ref-type="aff" rid="AFF1"><sup>a</sup></xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Bhakuni</surname>
                        <given-names>Rajendra S.</given-names>
                    </name>
                    <xref ref-type="aff" rid="AFF2"><sup>b</sup></xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Chinniah</surname>
                        <given-names>Annalakshmi</given-names>
                    </name>
                    <xref ref-type="aff" rid="AFF1"><sup>a</sup></xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Pal</surname>
                        <given-names>Anirban</given-names>
                    </name>
                    <xref ref-type="aff" rid="AFF2"><sup>b</sup></xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Kar</surname>
                        <given-names>Sudip K.</given-names>
                    </name>
                    <xref ref-type="aff" rid="AFF1"><sup>a</sup></xref>
                </contrib>
                <contrib contrib-type="author">
                    <name>
                        <surname>Das</surname>
                        <given-names>Pratap K.</given-names>
                    </name>
                    <xref ref-type="aff" rid="AFF1"><sup>a</sup></xref>
                </contrib>
            </contrib-group>
            <aff id="AFF1"><label>a</label>CSIR&#x2013;Indian Institute of Chemical Biology,
                Kolkata, India</aff>
            <aff id="AFF2"><label>b</label>CSIR&#x2013;Central Institute of Medicinal and Aromatic
                Plants, Lucknow, India</aff>
            <author-notes>
                <corresp>Address correspondence to Rajendra S. Bhakuni,
                        <email>rs.bhakuni@cimap.res.in</email>, or Pratap K. Das,
                        <email>pratapiicbdas@yahoo.com</email>.</corresp>
            </author-notes>
            <pub-date pub-type="ppub">
                <month>9</month>
                <year>2012</year>
            </pub-date>
            <volume>56</volume>
            <issue>9</issue>
            <fpage>4594</fpage>
            <lpage>4607</lpage>
            <history>
                <date date-type="received">
                    <day>22</day>
                    <month>2</month>
                    <year>2012</year>
                </date>
                <date date-type="rev-recd">
                    <day>23</day>
                    <month>3</month>
                    <year>2012</year>
                </date>
                <date date-type="accepted">
                    <day>2</day>
                    <month>6</month>
                    <year>2012</year>
                </date>
            </history>
            <copyright-statement>Copyright &#x00A9; 2012, American Society for Microbiology. All
                Rights Reserved.</copyright-statement>
            <copyright-year>2012</copyright-year>
            <self-uri xmlns:xlink="http://www.w3.org/1999/xlink"
                xlink:href="http://aac.asm.org/cgi/content/full/56/9/4594"
                >http://aac.asm.org/cgi/content/full/56/9/4594</self-uri>
            <self-uri xmlns:xlink="http://www.w3.org/1999/xlink"
                xlink:href="http://aac.asm.org/cgi/reprint/56/9/4594"
                >http://aac.asm.org/cgi/reprint/56/9/4594</self-uri>
            <self-uri xmlns:xlink="http://www.w3.org/1999/xlink"
                xlink:href="http://aac.asm.org/cgi/content/abstract/56/9/4594"
                >http://aac.asm.org/cgi/content/abstract/56/9/4594</self-uri>
            <abstract>
                <p>The antimalarial drug artemisinin from <italic>Artemisia annua</italic>
                    demonstrated remarkably strong activity against <italic>Helicobacter
                        pylori</italic>, the pathogen responsible for peptic ulcer diseases. In an
                    effort to develop a novel antimicrobial chemotherapeutic agent containing such a
                    sesquiterpene lactone endoperoxide, a series of analogues (2 natural and 15
                    semisynthetic molecules), including eight newly synthesized compounds, were
                    investigated against clinical and standard strains of <italic>H.
                    pylori</italic>. The antimicrobial spectrum against 10 <italic>H.
                        pylori</italic> strains and a few other bacterial and fungal strains
                    indicated specificity against the ulcer causing organism. Of five promising
                    molecules, a newly synthesized ether derivative &#x03B2;-artecyclopropylmether
                    was found to be the most potent compound, which exhibited MIC range,
                        MIC<sub>90</sub>, and minimum bactericidal concentration range values of
                    0.25 to 1.0 &#x03BC;g/ml, 1.0 &#x03BC;g/ml, and 1 to 16 &#x03BC;g/ml,
                    respectively, against both resistant and sensitive strains of <italic>H.
                        pylori</italic>. The molecule demonstrated strong bactericidal kinetics with
                    extensive morphological degeneration, retained functional efficacy at stomach
                    acidic pH unlike clarithromycin, did not elicit drug resistance unlike
                    metronidazole, and imparted sensitivity to resistant strains. It is not
                    cytotoxic and exhibits <italic>in vivo</italic> potentiality to reduce the
                        <italic>H. pylori</italic> burden in a chronic infection model. Thus,
                    &#x03B2;-artecyclopropylmether could be a lead candidate for anti-<italic>H.
                        pylori</italic> therapeutics. Since the recurrence of gastroduodenal ulcers
                    is believed to be mainly due to antibiotic resistance of the commensal organism
                        <italic>H. pylori</italic>, development of a candidate drug from this
                    finding is warranted.</p>
            </abstract>
            <custom-meta-wrap>
                <custom-meta>
                    <meta-name>coverdate</meta-name>
                    <meta-value>September 2012</meta-value>
                </custom-meta>
            </custom-meta-wrap>
        </article-meta>
    </front>
</article>
